SOURCE: Duravest, Inc.

June 12, 2006 00:30 ET

Duravest Lead Sponsor of BioDevice Partnering Conference June 13 and 14

Dr. Ogan Gurel, Duravest CEO, to Discuss Innovative Investment Strategies for Next-Generation Convergent/Combination Medical Technologies

CHICAGO, IL and EDINBURGH, SCOTLAND -- (MARKET WIRE) -- June 12, 2006 -- Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV), a unique company that strategically acquires, develops, and accelerates next-generation convergent medical technology firms, is a lead sponsor of the First Annual International BioDevice Partnering conference in Edinburgh, Scotland on June 13 and 14, 2006.

Dr. Ogan Gurel, CEO of Duravest, will be giving both a company presentation and participating as a keynote panelist at BioDevice Partnering. The conference will focus on fostering business opportunities involving convergent medical technologies and, in particular, the combination between medical device companies and the biotechnology and pharmaceutical industries. Other industry sectors such as tissue regeneration, biomaterials, medical nanotechnology, coatings and biopolymers will be featured.

On Tuesday, June 13, Dr. Gurel will be giving a company presentation to investors and conference attendees and will have the opportunity to discuss Duravest's innovative business model and strategy going forward. He will also be giving an update on the company's two current subsidiaries: PST GmbH, and Estracure Inc.

On Wednesday, June 14, Dr. Gurel will be participating on a panel entitled "The Investors' Opinion: Hot technologies, Innovative Business Models, Valuation and Challenges." The panel will be moderated by Mike Ward, Senior Editor of BioCentury Publications, Inc., and will include Berthold Hackl, Managing Partner of Heidelberg Innovation Group, Dr. Ruediger Herrmann, Partner at Mayer, Brown, Rowe & Maw, LLP, and Dr. Simon Turton, Managing Director of Warburg Pincus International, LLC.

The purpose of the panel is to further explore the challenges and opportunities investors face as convergent medical technologies become increasingly prevalent. New strategies for determining valuation and growth assessment models will be a key focus of the panel.

"Medical technology convergence is a new, rapidly growing industry and falls between areas traditionally served by the investment and analyst communities," said Dr. Gurel, CEO of Duravest. "I look forward to presenting Duravest's innovative approach to this high growth marketplace and how we can assist the investment community in better understanding this important industry in order to more quickly bring safer and more effective solutions to patients."

Duravest, Inc.

Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc. -- based in Montreal, Canada -- which is developing a next-generation coronary stent based on proprietary 17-beta-estradiol and PST, GmbH -- based in Munich, Germany which currently markets patented bio-magnetic therapies for orthopedic conditions and their associated pain management. The Duravest strategy encompasses three themes: (1) rapid commercialization of next-generation medical technologies by providing its portfolio of subsidiaries with financial, operational and scientific support, (2) prioritization of safety and (3) development of convergent medical technologies that span the traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices. Please visit www.duravestinc.com for more information.

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information